Quince Therapeutics (QNCX)

• Market cap: $85.9M
• 1 day: 1.27%
• 5 days: 0.63%
• 1 month: -12.57%
• 3 months: 33.33%
• 6 months: 7.38%
• Year to date: -14.89%
• 1 year: 117.69%
• 5 years: -97%
• 10 years: -95.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Employees: 36

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

80% more capital invested

Capital invested by funds: $6.96M [Q1] → $12.5M (+$5.55M) [Q2]

14% more funds holding

Funds holding: 36 [Q1] → 41 (+5) [Q2]

4.78% more ownership

Funds ownership: 11.89% [Q1] → 16.67% (+4.78%) [Q2]

11% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 9

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4
• Avg. target: $6
• High target: $8

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert	$4	Buy Maintained	15 Aug 2025
JMP Securities Jonathan Wolleben	$8	Market Outperform Maintained	12 Aug 2025